1	mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol					
2	(PEG) contained in mRNA-based vaccine formulations					
3						
4	Juan Manuel Carreño ^{1,7&*} , Gagandeep Singh ^{1,7*} , Johnstone Tcheou ^{1,7} , Komal Srivastava ^{1,7} , Charle					
5	Gleason ^{1,7} , Hiromi Muramatsu ² , Parnavi Desai ^{1,7} , Judith A. Aberg ³ , Rachel L. Miller ⁴ , PARIS study					
6	group ^{1,7} , Norbert Pardi ² , Viviana Simon ^{1,3,5,6,7&} , Florian Krammer ^{1,6,7&}					
7						
8	PARIS study group: Angela A. Amoako, Dalles Andre, Katherine F. Beach, Maria C. Bermúdez-					
9	González, Gianna Y. Cai, Christian Cognigni, Daniel L. Floda, Giulio Kleiner, Neko Lyttle, Wanni					
10 11	A Mendez, Lubbertus CF Mulder, Annika Oostenink, Aria Rooker, Ashley Beathrese T. Salimbangon, Miti Saksena, Levy A. Sominsky					
12						
13	Affiliations					
14	¹ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA					
15	² Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA					
16	³ Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Icahn Schoo					
17	of Medicine at Mount Sinai, New York, NY, USA					
18	⁴ Division of Clinical Immunology, Department of Medicine, Icahn School of Medicine at Icahr					
19	School of Medicine at Mount Sinai, New York, NY, USA					
20	⁵ The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai,					
21	New York, NY, USA					
22	⁶ Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at					
23	Mount Sinai, New York, NY, USA					
24	⁷ Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at					
25	Mount Sinai, New York, NY, USA					
26	*Contributed equally					
27	^{&} To whom correspondance should be addressed: Florian Krammer					
28	(florian.krammer@mssm.edu), Viviana Simon (viviana.simon@mssm.edu) and Juan Manuel					
29	Carreño (jm.carreno@mssm.edu)					
30						

31 Abstract

32

33 Two messenger RNA (mRNA)-based vaccines are widely used globally to prevent coronavirus 34 disease 2019 (COVID-19). Both vaccine formulations contain PEGylated lipids in their composition, in the form of polyethylene glycol [PEG] 2000 dimyristoyl glycerol for mRNA-1273, 35 36 and 2 [(polyethylene glycol)-2000]-N,N-ditetradecylacetamide for BNT162b2. It is known that some PEGylated drugs and products for human use that contain PEG, are capable of eliciting 37 38 immune responses, leading to detectable PEG-specific antibodies in serum. In this study, we 39 determined if any of the components of mRNA-1273 or BNT162b2 formulations elicited PEG-40 specific antibody responses in serum by enzyme linked immunosorbent assay (ELISA). We 41 detected an increase in the reactivity to mRNA vaccine formulations in mRNA-1273 but not 42 BNT162b2 vaccinees' sera in a prime-boost dependent manner. Furthermore, we observed the 43 same pattern of reactivity against irrelevant lipid nanoparticles from an influenza virus mRNA 44 formulation and found that the reactivity of such antibodies correlated well with antibody levels 45 against high and low molecular weight PEG. Using sera from participants selected based on the 46 vaccine-associated side effects experienced after vaccination, including delayed onset, injection 47 site or severe allergic reactions, we found no obvious association between PEG antibodies and 48 adverse reactions. Overall, our data shows a differential induction of anti-PEG antibodies by 49 mRNA-1273 and BNT162b2. The clinical relevance of PEG reactive antibodies induced by 50 administration of the mRNA-1273 vaccine, and the potential interaction of these antibodies with 51 other PEGylated drugs remains to be explored.

- 52
- 53
- 54
- 55 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63

64 Introduction

65

66 Since their introduction, vaccines currently used to prevent coronavirus disease 2019 (COVID-19) 67 have been extensively scrutinized with regard to their safety profile. Some individuals developed 68 adverse reactions following the vaccine administration, such as pain, itching, redness, swelling, 69 and induration at the injection site, or general adverse reactions including cough, diarrhea, 70 fatigue, fever, and headache (1, 2). These side effects are unpleasant but generally are not 71 clinically serious. More severe but very rare side effects, including myocarditis and pericarditis 72 (40 cases per million vaccinated male 12-29 year old vaccinees) have been described (3-5) and 73 anaphylaxis (0.001 - 0.0001 % of the vaccinated population) also has been reported (2). 74 Importantly, higher self-reported reactogenicity following administration of mRNA-1273 (from 75 Moderna) versus BNT162b2 (from Pfizer) has been described (6). Delayed large local reactions, 76 which are harmless but can be concerning for vaccinees, have been reported specifically to occur 77 in mostly female vaccinees who received mRNA-1273 (7, 8). However, so far, the cause of these 78 differences between the two mRNA-based vaccine formulations remains unclear.

79

80 It is known that some of the excipients contained in different drugs for human use can cause local 81 or systemic reactions, resulting in the induction of immune responses towards some of these 82 components (9). Furthermore, it has been suggested that certain components of the mRNA 83 vaccine formulations might be involved in the development of some of the adverse reactions 84 observed, including anaphylaxis (2, 9). Pertaining to the structure and composition of the two 85 mRNA-based vaccine formulations, both vaccines consist of nucleoside-modified mRNA which 86 encodes a diproline (2P)-stabilized, full-length, membrane-bound spike protein (3). Likewise, 87 both formulations contain charged and non-charged ionizable lipids, which form the core of the 88 lipid nanoparticles (LNPs), while 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol 89 and a PEGylated lipids, give shape and stabilize the surface lipid bilayer (3) (Table 1). Particularly, 90 polyethylene glycol (PEG) contained in mRNA-based formulations may be linked to some cases 91 of anaphylaxis (10, 11). Indeed, the US Advisory Committee on Immunization Practices (ACIP) 92 recommended in the past the exclusion of people with known severe allergic reactions against 93 PEG and related compounds from receiving vaccine formulations containing these components

94 (12). Both, PEG and polysorbate 80, a component of the adenovirus vectored vaccine AZD1222,
95 as well as other compounds of similar nature, have been implicated in rare cases of
96 hypersensitivity reactions (9, 10, 13), and PEG is known to elicit antigen-specific antibody
97 responses in some individuals (10, 13-15).

99 Given that both of the current mRNA-based vaccine formulations - mRNA-1273 and BNT162b2 -100 contain PEG in their composition, but vaccinated individuals display differential reactogenicity, 101 we evaluated whether serum antibodies from mRNA-based vaccine recipients were able to react 102 with homologous/heterologous mRNA vaccine formulations. Furthermore, we assessed if 103 differential patterns of reactivity of antibodies elicited by mRNA-1273 or BNT162b2 were 104 observed, and assessed the target components within the vaccine formulation.

123 Materials and methods

124

126

125 Study participants and human samples

127 Samples were collected as part of our ongoing institutional review board-approved, longitudinal 128 observational studies (Study ID-20-00442: 64 participants; Study ID-16-01215: one participant). 129 The majority of samples were selected from the PARIS (Protection Associated with Rapid 130 Immunity to SARS-CoV-2) study, which follows healthcare workers (HCWs) of the Mount Sinai 131 Health System. All participants signed informed consents prior to data and sample collection. 132 Information on SARS-CoV-2 mRNA vaccine-associated side-effects were collected using a survey 133 sent to the participants after the first and second vaccine dose. Samples were coded and analyzed 134 in a blinded manner.

Sixty longitudinal samples from 20 PARIS participants (10 BNT162b2 vaccinees and 10 mRNA-136 1273 vaccinees) were selected at baseline, 18.9 days (arithmetic mean ±2.4 SD) after the first 137 SARS-CoV-2 mRNA vaccine dose (prime) and 19.3 days (arithmetic mean ±3.9 SD) after the 138 second SARS-CoV-2 mRNA vaccine dose (boost).

In addition, we selected longitudinal serum samples collected from participants who reported experiencing more pronounced, unusual or delayed onset vaccine-associated side effects (7 days arithmetic mean ±5.2 SD) after the first mRNA vaccine dose. The sera were collected at baseline (n=28 for BNT162b2 and n=19 for mRNA-1273 groups), 14.5 days (arithmetic mean ±4.8 SD) after the prime (n=23 for BNT162b2 and n=17 for mRNA-1273 groups) and 25.2 days (arithmetic mean ±11.6 SD) after the boost (n=26 for BNT162b2 and n=17 for mRNA-1273 groups).

145 The SARS-CoV-2 mRNA vaccine side effects reported from the participants selected based on 146 their vaccine associated side effects were generally mild to moderate and self-limiting (e.g., 147 injection site pain/swelling, fever, fatigue, etc.) with a subset of participants (N: 8, all females, 148 three received BNT162b2 and five received mRNA-1273) reporting delayed onset, injection site 149 rashes, redness or swelling. Of note, all five participants receive a second vaccine dose and the 150 delayed onset skin reactions did not re-occur. Sera from a female participant who developed a 151 severe allergic reaction after the first BNT162b2 vaccine dose requiring hospitalization were also 152 included. This participant did not receive a second vaccine dose.

153 Irrelevant mRNA-LNP production

154 The mRNA used as an irrelevant control was designed based on the influenza virus 155 B/Colorado/06/2017 neuraminidase (NA) sequence. Production of the mRNA was performed as 156 described earlier (16, 17). Briefly, the codon-optimized NA gene was synthesized (Genscript) and 157 cloned into an mRNA production plasmid. A T7-driven *in vitro* transcription reaction (Megascript, 158 Ambion) using linearized plasmid template was performed to generate mRNA with 101 159 nucleotide long poly(A) tail. Capping of the mRNA was performed in concert with transcription 160 through addition of a trinucleotide cap1 analogue, CleanCap (TriLink) and m1 Ψ -5'-triphosphate 161 (TriLink) was incorporated into the reaction instead of UTP. Cellulose-based purification of NA 162 mRNA was performed as described (18). The mRNA was then tested on an agarose gel before 163 storing at -20°C.

164 The cellulose-purified m1 Ψ -containing NA mRNA was encapsulated in LNPs using a 165 self-assembly process as previously described wherein an ethanolic lipid mixture of ionizable 166 cationic lipid, phosphatidylcholine, cholesterol and polyethylene glycol-lipid was rapidly mixed 167 with an aqueous solution containing mRNA at acidic pH (19). The RNA-loaded particles were 168 characterized and subsequently stored at - 80°C at a concentration of 1 mg/ml.

169

170 Expression and purification of recombinant SARS-CoV-2 spike protein. Recombinant SARS-CoV-171 2 spike protein was produced using a mammalian cell protein expression system. Briefly, the 172 spike (S) gene sequence (GenBank: MN908947) was cloned into a mammalian expression vector 173 pCAGGs, as described (20, 21). Protein was expressed using the Expi293 Expression System 174 (Thermo Fisher Scientific), according to the manufacturer's instructions. Cell culture supernatant 175 was collected and clarified by centrifugation at 4000 x g, filtered, and purified with Ni-176 nitrilotriacetic acid (NTA) agarose (QIAGEN). The purified protein was concentrated using Amicon 177 Ultracell (Merck Millipore) centrifugation units, and the buffer was exchanged to a phosphate 178 buffer solution (PBS, pH 7.4). Proteins were stored at -80°C until use.

179

180 **Enzyme linked immunosorbent assay (ELISA).** Antibody titers in vaccinees' sera were 181 determined against the recombinant trimeric spike protein of wild type SARS-CoV-2 as previously 182 described (21, 22). Spike and BSA ELISAs were performed using phosphate-buffered saline (PBS)

183 with 0.1% Tween-20 (PBS-T; Fisher Scientific) in washing, blocking, and diluting solutions. mRNA 184 vaccines BNT162b2 (from Pfizer) and mRNA-1273 (from Moderna), irrelevant mRNA LNPs, multi-185 PEGylated bovine serum albumin (mPEG-BSA, 20 kDa, Life Diagnostics, Inc), and low molecular 186 weight PEG (3.35kDa, Sigma) based ELISAs were performed using a modified protocol in which 187 Tween-20 was excluded from washing/Ab solutions. Briefly, polystyrene 96-well microtiter plates 188 (Thermo Fisher Scientific) were coated overnight with mPEG-BSA (2µg/ml), BNT162b2 or mRNA-189 1273 vaccine formulations (25µl/10ml), irrelevant mRNA lipid nanoparticles (0.5µg/ml) or BSA 190 (1% solution, MP Biomedicals). For IgE and BSA controls (shown in Supplementary Figure 2), ELISA 191 plates were coated with 2µg/ml of an IgE isotype control (Invitrogen) and BSA (1% solution, MP 192 Biomedicals) respectively. The following day, wells were washed and blocked with 200 ul of 3% 193 non-fat milk (AmericanBio) in PBS for 1 h at room temperature (RT). After 1 h incubation, blocking 194 solution was removed and pre-diluted sera (in PBS 1% non-fat milk) were added at an initial 195 dilution of 1:50 followed by 2-fold serial dilutions. After 2 h incubation, plates were washed three 196 times with PBS and then incubated for 1 hour with anti-human IgG (Fab-specific) horse radish 197 peroxidase (HRP) secondary antibody produced in goat (Sigma-Aldrich), or IgM-HRP (Southern 198 Biotech) at a 1:3000 in 1% milk PBS. Specific spike/PEG-IgE antibodies were assessed by 199 incubating with an anti-IgE HRP conjugated antibody (Invitrogen) for 1 h at a 1:2000 dilution. For 200 the IgE control, plates were incubated with serial dilutions (2-fold) of the anti-IgE HRP conjugated 201 antibody (Invitrogen) starting at a 1:1000 dilution for 1 h. For the BSA control, plates were 202 incubated with serial dilutions (2-fold) of an anti-albumin (bovine serum) rabbit IgG fraction (anti-203 BSA, Invitrogen) starting at a 1:1000 dilution for 1 h, followed by three washes with PBS and 204 addition of a donkey anti-rabbit IgG HRP conjugated antibody (CiteAb) at a 1:1000 dilution. Plates 205 were washed three times with PBS and 100μ /well of *O*-phenylenediamine dihydrochloride (OPD) 206 substrate (SigmaFast OPD; Sigma-Aldrich) were added. After 10 min incubation at RT, the 207 reaction was stopped by addition of 50 μ l of 3 M HCl solution. The optical density (OD) was 208 measured at 490 nm using a Synergy 4 plate reader (BioTek). Data were captured in excel and 209 are urea under the curve (AUC) values were determined using Prism 9 (GraphPad Software, San 210 Diego, CA, USA).

Statistical analyses. Data plotting and statistical analyses were performed using GraphPad Prism 9 (GraphPad Software, San Diego, CA, USA). Statistically significant differences between postprime/post-boost vs baseline antibody levels were measured using a one-way ANOVA with Tukey's multiple comparisons test. All adjusted P values of <0.05 were considered statistically significant with a confidence interval of 95%.

216

217 Results

218 mRNA-1273 vaccination induces antibodies against mRNA vaccine formulations in a prime-219 **boost dependent manner**. It has been hypothesized that the adverse reactions observed in some 220 individuals after administration of the currently available mRNA vaccines might be caused by 221 some of the formulation components (2, 11). To explore if vaccinees elicited antibodies against 222 components of the vaccine formulation, we used samples from individuals who received either 223 the mRNA-1273 or BNT162b2 mRNA vaccines. Samples were collected at baseline (n=10/group), 224 18.9 days (arithmetic mean ±2.4 SD) after the prime (n=10/group) or 19.3 days (arithmetic mean 225 ± 3.9 SD) after the boost (n=10/group). Initially, to confirm the induction of antibodies after the 226 vaccine administration, we measured the IgG titers against a recombinant version of the spike 227 protein via ELISA. We detected a prime-boost dependent induction of anti-spike antibodies after vaccination, with levels oscillating around 10³ area under the curve (AUC) units after prime with 228 229 mRNA-1273 or BNT162b2, and 10^4 after the boost administration (Figs. **1A** and **1B**). Then, we 230 coated ELISA plates with a standard amount of each of the vaccine formulations resuspended in 231 PBS and assessed binding of IgG antibodies. We found that sera collected after vaccination with 232 mRNA-1273 had increasing reactivity against both the BNT162b2 (Fig. 1C) and mRNA-1273 (Fig. 233 **1D**) formulations, and that the increased reactivity was vaccination-dependent, with a moderate 234 increase after the prime administration and higher levels induced after the boost. Interestingly, 235 this increase in reactivity was not evident in sera from individuals receiving the BNT162b2 236 vaccine, either against the BNT162b2 or mRNA-1273 formulations (Figs. 1E and 1F). Overall, these 237 data suggest that mRNA-1273 but not BNT162b2 vaccination induces antibodies against some 238 component(s) of the vaccine formulations.

239 Antibodies reactive towards the vaccine formulation are directed against the lipid 240 nanoparticles and react with polyethylene glycol (PEG). Lipid nanoparticles contained in the 241 currently used mRNA vaccine formulations, as well as other drugs and other cosmetic and health 242 products for human use, contain PEG and have the potential to elicit immune responses against 243 it (10, 13-15). To dissect the target within the vaccine formulation to which mRNA-1273-induced 244 antibodies bind, we coated ELISA plates with LNPs carrying a SARS-CoV-2 unrelated, irrelevant 245 mRNA (encoding influenza virus neuraminidase). Similar to the reactivity overserved against the 246 BNT162b2 and mRNA-1273 formulations, we detected an increase in the reactivity against the 247 irrelevant mRNA-LNPs in individuals receiving the mRNA-1273 vaccine (Fig. 2B), but not in those 248 ones vaccinated with BNT162b2 (Fig. 2A), suggesting the reactivity is independent of the 249 sequence of the mRNA contained in the formulation.

250

251 Next, we assessed whether vaccination induced antibodies reacted to PEG. We measured the 252 binding of sera from mRNA-1273 and BNT162b2 vaccinated individuals to a PEGylated form of 253 BSA (PEG-BSA) containing high molecular weight PEG (20kDa). Again, we found that individuals 254 vaccinated with mRNA-1273, had an increase in antibodies against PEG-BSA in a vaccination-255 dependent manner (Fig. 2D), whereas no significant increase of antibody titers in individuals 256 receiving the BNT162b2 vaccine was observed (Fig. 2C). As an alternative experimental approach, 257 we coated high binding polystyrene plates directly with a low molecular weight PEG (3.35 kDa) 258 molecule and performed similar ELISAs. Although this method seemed to be less sensitive than 259 the PEG-BSA ELISA, similarly we observed that individuals vaccinated with mRNA-1273, had 260 increased reactivity to PEG, particularly after the boost (Fig. 2E), but there was no increase in 261 antibody titers following BNT162b2 administration (Fig. 2F). Overall, these results suggest that 262 the antibodies induced towards the vaccine formulation components may be directed against 263 PEG, which is present in the vaccine formulation.

264

PEG as the target of mRNA-1273-induced antibodies. To assess in a systematic manner if the formulation-reactive antibodies induced in mRNA-1273 vaccine recipients were directed against PEG, we performed correlation analyses using the AUC values obtained in the different ELISAs

268 performed. We found that the mRNA-1273 induced antibodies detected against the BNT162b2 269 (Fig. 3A) or mRNA-1273 (Fig. 3B) vaccine formulations not only correlated well with PEG as 270 measured by using PEGylated BSA, but a correlation was observed between the PEGylated-BSA 271 AUC values and the irrelevant mRNA-LNPs (Fig. 3C), as well as with the low molecular weight PEG 272 (3.35kDa) AUCs (Fig. **3D**). Moreover, the independent correlation of PEGylated-BSA AUC values 273 vs the BNT162b2 or mRNA-1273 formulation, the irrelevant mRNA-LNPs, or the low molecular 274 weight PEG AUCs, increased in a prime-boost dependent manner, with the lowest correlation 275 observed at baseline, and increasing correlations after the prime, followed by high correlations 276 after the boost (Supplementary Fig. 1). The absolute values of the geometric mean AUCs for every 277 ELISA and the fold induction after the prime or the boost are shown in **Table 2**. Overall, these 278 analyses support that the antibodies detected in mRNA-1273 vaccine recipients, which react 279 towards the BNT162b2 or mRNA-1273 vaccine formulations, are directed towards the PEG 280 component of the formulations.

281

282 To explore if vaccinees displayed other classes of anti-PEG antibodies, we measured the reactivity 283 of IgM using the PEGylated BSA based ELISA. Similar to the IgG pattern previously observed, we 284 detected PEG-specific IgM - although at low levels - in the mRNA-1273 recipients in a vaccination 285 dependent manner (Fig. 4B), however no induction of IgM in the BNT162b2 vaccinees (Fig. 4A). 286 Moreover, we assessed whether individuals could potentially induce IgE antibodies directed to 287 PEG in response to vaccination, however levels of PEG-specific IgE were undetectable in all the 288 participants, irrespective of the vaccine type received (Figs. 4C and 4D). As a control for IgE 289 detection, we used plates coated with house dust mite (HDM) antigens, which allowed detecting 290 IgE in some of the participants (Supplementary Fig. 2). Moreover, as a control to ensure that the 291 anti-PEG antibodies detected through this work were directed specifically against PEG, and 292 exclude the possibility that the BSA contained in the PEG-BSA reagent was as a target of the 293 reactivity detected, we performed ELISAs in plates pre-coated with 1% BSA (Figs. 4E and 4F). We 294 detected residual reactivity in three individuals, although at levels very close to the limit of 295 detection. These residual antibodies were, however, detected in both the BNT162b2 and mRNA-1273 groups, and were irrespective of the vaccination time point. Overall, these results indicate 296

that mRNA-1273 administration leads to the induction of specific IgG and IgM, but not IgEantibodies against PEG.

Anti-PEG antibodies in a subgroup of participants with reported vaccine associated side effects including delayed onset, injection site rash/erythema or severe allergic reaction. A small proportion of individuals have experienced delayed large local reactions after receiving the mRNA-1273 vaccine (7, 8). To assess whether individuals who experienced delayed onset reactions or other types of adverse reactions following vaccination, mounted differential anti-PEG antibodies at baseline or after vaccination, we used samples from a selection of study participants that reported vaccine-associated side effects such as delayed onset reactions including injection site rashes (N=8) or severe allergic reaction (N=1). Overall, although levels of anti-PEG antibodies were slightly higher at baseline, we did not find a significant association between baseline anti-PEG titers and antibody induction after vaccination with mRNA-1273 or BNT162b2. However, individuals receiving the mRNA-1273 formulation (Fig. 5B), but not the ones receiving the BNT162b2 vaccine (Fig. 5A), induced significantly higher levels of anti-PEG antibodies in a vaccination-dependent manner, similar to the findings described above. In summary, these findings indicate that although there is an increase in the anti-PEG antibodies in the mRNA-1273 vaccinees, there was no obvious association between PEG antibodies and adverse reactions. Pre-existing anti-PEG levels are not associated with a more robust PEG antibody induction following vaccination.

331 Discussion

332

333 Some of the current vaccines to prevent COVID-19 have unique properties as compared to any 334 other licensed vaccines in history. They are based on mRNA encapsulated in lipid nanoparticles 335 and they do not contain the target antigen which is coded by the mRNA and produced in the 336 vaccinee's cells. The LNPs contain lipidic components of diverse nature including PEGylated lipids. 337 Polyethylene glycol (PEG) is found in different drugs, cosmetics and health products for human 338 use (10, 23). Administration of animals with PEGylated proteins of different nature can induce 339 PEG-specific antibodies (24). Likewise, humans are able to induce anti-PEG antibodies following 340 administration of certain PEGylated drugs (14, 25-27). Moreover, pre-existing anti-PEG 341 antibodies are present in some individuals and can interfere with activities of PEGylated drugs 342 (15, 28).

343

344 Here, we found that a proportion of study participants receiving SARS-CoV-2 mRNA vaccines 345 mount anti-PEG antibodies to variable levels. Not every study participant receiving the mRNA-346 1273 vaccine displayed high levels of anti-PEG antibodies post-vaccination, and not every 347 individual experiencing delayed onset side effects such as injection site reactions post-348 vaccination had pre-existing anti-PEG levels. This suggests that although PEG contained in the 349 mRNA-1273 vaccine formulation is recognized by the immune system and antibodies are induced 350 against this molecule in some of the vaccinees, such high levels of antibodies – either at baseline 351 or induced by vaccination – do not directly correlate with the emergence of delayed large local 352 reactions. Although we cannot establish an association between the levels of PEG-reactive 353 antibodies and the higher reactogenicity observed in mRNA-1273 vaccinees, our findings suggest 354 that perhaps anti-formulation immune responses are contributing to the higher reactogenicity 355 sometimes observed with mRNA-1273 compared to BNT162b2.

356

The pre-existing antibody levels against PEG could be due to previous exposures to PEGylated drugs (14, 25-27) or PEG-containing products (23). Importantly, we assessed the presence of spike- or PEG- specific IgE antibodies and we did not find detectable levels of IgE antibodies, including in the one participant who experienced a severe allergic reaction in response to

361 vaccination. Our results are in line with previous findings detecting PEG-specific IgG following 362 vaccination, but a lack of IgE (29). Allergy skin testing to PEG also was negative (unpublished 363 data). Immediate allergic reactions following vaccination, such anaphylaxis, are likely to be 364 mediated by IgE-independent mechanisms of diverse nature (29), and the relevance of PEG-365 specific IgG induced by vaccination remains to be investigated. Interestingly, via a genome-wide 366 association study, an immunoglobulin heavy chain (IGH) locus has been associated with the anti-367 PEG IgM response (30). Although such association was not present for IgG, IGH polymorphisms 368 associated with switched anti-PEG IgG subsets require further exploration.

369

370 Differential immunogenicity of PEG molecules containing a methoxy (mPEG), hydroxy (H)-PEG) 371 or t-butoxy (t-BuO-PEG) distal terminal groups has been described, with mPEG being more prone 372 to induce specific responses against this terminal group (31). Notwithstanding, the majority PEG-373 specific monoclonal antibodies (mAbs) recognize the backbone of the molecule, meaning the 374 repeated ethylene oxide subunits (28, 32-34). Although the currently used mRNA formulations 375 incorporate different forms of PEG, both the polyethylene glycol [PEG] 2000 dimyristoyl glycerol 376 contained in the mRNA-1273 formulation, and the 2 [(polyethylene glycol)-2000]-N,N-377 ditetradecylacetamide contained in the BNT162b2 formulation, bear a methoxy terminal group. 378 Hence, it is unlikely that the differential patterns of anti-PEG antibodies detected in mRNA-1273 379 vs BNT162b2 vaccinee's sera, are due to PEG structural differences in the formulations, but 380 rather, this might be the result of the higher dose of mRNA given to mRNA-1273 vaccine 381 recipients - 100µg for mRNA-1273 vs 30µg for BNT162b2, the result of the higher PEGylated lipid 382 dose in mRNA-1273 or the way PEG is presented by the carrier lipid (35). Moreover, serum from 383 mRNA-1273 vaccine recipients was able to recognize components of both formulations in a 384 prime-boost dependent manner. It remains to be explored whether the anti-PEG antibodies 385 induced following vaccination are directed towards the backbone of the PEG molecule, or the 386 methoxy group present in PEG from both formulations. Overall, our study reports the induction 387 of PEG antibodies following administration of one of the currently used mRNA-based vaccine 388 formulation. The clinical relevance of PEG-reactive antibodies induced by mRNA-1273

administration and the potential interaction of these antibodies with other PEGylated drugsremain to be explored.

391

392 Acknowledgments

393 We thank the study participants for their generosity and willingness to participate in longitudinal 394 COVID-19 research studies. None of this work would be possible without their contributions. 395 This work is part of the PARIS/SPARTA studies funded by the NIAID Collaborative Influenza 396 Vaccine Innovation Centers (CIVIC) contract 75N93019C00051. In addition, this work was also 397 partially funded by NIAID U19AI168631-01 and the Centers of Excellence for Influenza Research 398 and Surveillance (CEIRS, contract # HHSN272201400008C), the JPB Foundation, the Open 399 Philanthropy Project (research grant 2020-215611 (5384) and by anonymous donors. Finally, this 400 effort was also supported by the Serological Sciences Network (SeroNet) in part with Federal 401 funds from the National Cancer Institute, National Institutes of Health, under Contract No. 402 75N91019D00024, Task Order No. 75N91021F00001. The content of this publication does not 403 necessarily reflect the views or policies of the Department of Health and Human Services, nor 404 does mention of trade names, commercial products or organizations imply endorsement by the 405 U.S. Government. We thank Acuitas Therapeutics for LNP-encapsulating the NA mRNA used in 406 this study.

407

408 **Conflict of interest statement**

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as coinventor. Viviana Simon is also listed on the serological assay patent application as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures, Merck and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2.

- 410
- 417

418 **Author contributions:**

- 419 F.K., V.S. and J.M.C. conceptualized study; CG, KS and the PARIS study group enrolled participants,
- 420 collected data, evaluated surveys and provided biospecimen and metadata, G.S., J.M.C, C.G.,
- 421 H.M., J.T., P.D. and the PARIS study group performed experiments; J.M.C., G.S., and J.T. analyzed
- 422 data; J.M.C., V.S., and F.K. administered the project; F.K., V.S., and N.P. provided resources; J.M.C.
- 423 wrote original draft. All authors reviewed, edited and approved the final version of the
- 424 manuscript, and have had access to the raw data.
- 425

426 **References**

427

Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, et al. Safety of SARS-CoV-2 vaccines: a
 systematic review and meta-analysis of randomized controlled trials. Infect Dis Poverty.
 2021;10(1):94.

- 431 2. Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med.
 432 2021;384(7):643-9.
- 433 3. Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D.
 434 Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines (Basel). 2021;9(1).
- 4. Wallace M, Moulia D, Blain AE, Ricketts EK, Minhaj FS, Link-Gelles R, et al. The Advisory 436 Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine 437 in Adults Aged >/=18 Years and Considerations for Extended Intervals for Administration of 438 Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022. MMWR Morb 439 Mortal Wkly Rep. 2022;71(11):416-21.
- 440 5. Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis Cases Reported
 441 After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA.
 442 2022;327(4):331-40.
- 443 6. Chapin-Bardales J, Gee J, Myers T. Reactogenicity Following Receipt of mRNA-Based 444 COVID-19 Vaccines. JAMA. 2021;325(21):2201-2.
- 4457.Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, et al. Delayed446Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2. N Engl J Med.4472021;384(13):1273-7.
- 4488.Johnston MS, Galan A, Watsky KL, Little AJ. Delayed Localized Hypersensitivity Reactions449to the Moderna COVID-19 Vaccine: A Case Series. JAMA Dermatol. 2021;157(6):716-20.
- 450 9. Stone CA, Jr., Rukasin CRF, Beachkofsky TM, Phillips EJ. Immune-mediated adverse 451 reactions to vaccines. Br J Clin Pharmacol. 2019;85(12):2694-706.
- 452 10. Chen BM, Cheng TL, Roffler SR. Polyethylene Glycol Immunogenicity: Theoretical, Clinical,
 453 and Practical Aspects of Anti-Polyethylene Glycol Antibodies. ACS Nano. 2021;15(9):14022-48.
- 454 11. Klimek L, Novak N, Cabanillas B, Jutel M, Bousquet J, Akdis CA. Allergenic components of
- 455 the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-456 mediated complement activation. Allergy. 2021;76(11):3307-13.

457 12. Dooling K, McClung N, Chamberland M, Marin M, Wallace M, Bell BP, et al. The Advisory
458 Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of
459 COVID-19 Vaccine - United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(49):1857-9.

460 13. Caballero ML, Krantz MS, Quirce S, Phillips EJ, Stone CA, Jr. Hidden Dangers: Recognizing
461 Excipients as Potential Causes of Drug and Vaccine Hypersensitivity Reactions. J Allergy Clin
462 Immunol Pract. 2021;9(8):2968-82.

463 14. Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS. Induced and pre-464 existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for 465 refractory gout, including in organ transplant recipients. Arthritis Res Ther. 2014;16(2):R63.

466 15. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, et al. Antibody against
467 poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic
468 leukemia patients. Cancer. 2007;110(1):103-11.

Freyn AW, Ramos da Silva J, Rosado VC, Bliss CM, Pine M, Mui BL, et al. A Multi-Targeting,
Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. Mol Ther.
2020;28(7):1569-84.

472 17. Freyn AW, Pine M, Rosado VC, Benz M, Muramatsu H, Beattie M, et al. Antigen
473 modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice. Mol
474 Ther Methods Clin Dev. 2021;22:84-95.

475 18. Baiersdorfer M, Boros G, Muramatsu H, Mahiny A, Vlatkovic I, Sahin U, et al. A Facile
476 Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA. Mol Ther
477 Nucleic Acids. 2019;15:26-35.

478 19. Sternfeld M, Finkelstein Y, Hai E, Hod I. Tension headache treated by anti-inflammatory
479 drug injected into GB 20 acupuncture point. Am J Chin Med. 1986;14(3-4):171-4.

48020.Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A481serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26(7):1033-6.

48221.Stadlbauer D, Tan J, Jiang K, Hernandez MM, Fabre S, Amanat F, et al. Repeated cross-483sectional sero-monitoring of SARS-CoV-2 in New York City. Nature. 2021;590(7844):146-50.

484 22. Carreno JM, Alshammary H, Singh G, Raskin A, Amanat F, Amoako A, et al. Evidence for
485 retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum
486 of COVID-19 mRNA vaccine recipients. EBioMedicine. 2021;73:103626.

487 23. Fruijtier-Polloth C. Safety assessment on polyethylene glycols (PEGs) and their derivatives
488 as used in cosmetic products. Toxicology. 2005;214(1-2):1-38.

Richter AW, Akerblom E. Antibodies against polyethylene glycol produced in animals by
immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl
Immunol. 1983;70(2):124-31.

492 25. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in 493 subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a 494 phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther. 2006;8(1):R12.

495 26. Longo N, Harding CO, Burton BK, Grange DK, Vockley J, Wasserstein M, et al. Single-dose,

496 subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in

497 adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial.
498 Lancet. 2014;384(9937):37-44.

Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, et al. Pharmacokinetics
and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in
patients with refractory gout. Arthritis Rheum. 2007;56(3):1021-8.

502 28. Yang Q, Lai SK. Anti-PEG immunity: emergence, characteristics, and unaddressed 503 questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7(5):655-77.

504 29. Warren CM, Snow TT, Lee AS, Shah MM, Heider A, Blomkalns A, et al. Assessment of 505 Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a 506 US Regional Health System. JAMA Netw Open. 2021;4(9):e2125524.

507 30. Chang CJ, Chen CH, Chen BM, Su YC, Chen YT, Hershfield MS, et al. A genome-wide 508 association study identifies a novel susceptibility locus for the immunogenicity of polyethylene 509 glycol. Nat Commun. 2017;8(1):522.

510 31. Sherman MR, Williams LD, Sobczyk MA, Michaels SJ, Saifer MG. Role of the methoxy 511 group in immune responses to mPEG-protein conjugates. Bioconjug Chem. 2012;23(3):485-99.

512 32. Cheng TL, Cheng CM, Chen BM, Tsao DA, Chuang KH, Hsiao SW, et al. Monoclonal 513 antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and 514 nanoparticles. Bioconjug Chem. 2005;16(5):1225-31.

515 33. Tsai NM, Cheng TL, Roffler SR. Sensitive measurement of polyethylene glycol-modified 516 proteins. Biotechniques. 2001;30(2):396-402.

517 34. Su YC, Chen BM, Chuang KH, Cheng TL, Roffler SR. Sensitive quantification of PEGylated 518 compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. Bioconjug 519 Chem. 2010;21(7):1264-70.

520 35. Risma KA, Edwards KM, Hummell DS, Little FF, Norton AE, Stallings A, et al. Potential 521 mechanisms of anaphylaxis to COVID-19 mRNA vaccines. J Allergy Clin Immunol. 522 2021;147(6):2075-82 e2.

- 523
- 524
- 525
- 526
- 527 528
- 529
- 530
- 531
- 532 533
- 534
- 535
- 536

537 538

- 539
- 540

541

Table 1. Components of mRNA-1273 and BNT162b2 formulations.

•	mRNA-1273	BNT162b2	
Nucleic acid	messenger ribonucleic acid (mRNA)	messenger ribonucleic acid (mRNA)	
	SM-102	ALC 315	
Lipidic	polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG]	2 [(polyethylene glycol)-2000]-N,N- ditetradecylacetamide	
components	Cholesterol	Cholesterol	
	1,2-distearoyl-sn-glycero-3- phosphocholine [DSPC]	1,2-Distearoyl-sn-glycero-3- phosphocholine [DSPC]	
Other components	Tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose	Tromethamine, tromethamine hydrochloride, and sucrose or* potassium chloride, monobasic potassium phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose	

*BNT162b2 vaccine for individuals 12 years of age and older contain one of the two sets of additional ingredients

		Geometric	mean AUCs	Geometric mean AUC fold	
				change	
	Timepoint/	BNT162b2	mRNA-1273	BNT162b2	mRNA-1273
	vaccine	G.M. AUC	G.M. AUC	(G.M.F.I)	(G.M.F.I)
Spike	Prime	1569.32	2043.64	313.86	408.73
	Boost	7405.92	7974.32	1481.18	1594.86
BNT162b2 LNP	Prime	0.54	1.54	0.92	2.25
	Boost	0.58	7.04	1.07	4.28
mRNA-1273	Prime	0.55	1.84	1.1	2.6
LNP	Boost	0.66	8.62	1.32	12.2
Nonspecific LNP	Prime	8.98	27.44	1.1	3.54
	Boost	9.6	49.39	1.07	2.12
PEGylated BSA	Prime	10.01	49.64	1.26	5.06
	Boost	8.87	169.14	1.11	17.25
Low molecular	Prime	0.5	0.89	1	1.78
weight PEG	Boost	0.61	1.78	1.22	9.29
BSA	Prime	5.43	5.38	0.92	0.96
	Boost	5.78	8.06	0.98	1.44

Table 2. Geometric means of AUC and AUC fold change for each ELISA antigen.

567 Geometric mean (G.M.) of all the area under the curve (AUC) values measured after the prime or the 568 boost are shown in the left panels. Geometric mean of fold induction (G.M.F.I) values, expressed as the 569 ratio between prime or boost AUCs and the baseline AUC for each of the participants is shown in the right 570 panels. Prime: First SARS-CoV-2 vaccine dose; Boost: Second SARS-CoV-2 vaccine dose

589 Figure Legends

590

591 Figure 1. Antibodies against SARS-CoV-2 spike and mRNA-based vaccine formulations in 592 vaccinees' sera. Sera from BNT162b2 (left column) or mRNA-1273 (right column) vaccinees 593 collected at baseline (n=10 for BNT162b2 and n=10 for mRNA-1273 groups), 18.9 days (arithmetic 594 mean ±2.4 SD) after the prime (n=10 for BNT162b2 and n=10 for mRNA-1273 groups) and 19.3 595 days (arithmetic mean ±3.9 SD) after the boost (n=10 for BNT162b2 and n=10 for mRNA-1273 596 groups), were tested for IgG antibodies against SARS-CoV-2 full-length spike (**A** and **B**), BNT162b2 597 mRNA LNPs (C and E), and mRNA-1273 mRNA LNPs (D and F) by ELISA. Dotted line represents the limit of detection (LOD) of the assay. Statistically significant differences between post-598 599 prime/post-boost vs baseline antibody levels are shown. One-way ANOVA with Tukey's multiple comparisons test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.001; 600

601

602 Figure 2. Antibodies against irrelevant lipid nanoparticles (LNPs) and polyethylene glycol (PEG)

603 in vaccinees' sera. Sera from BNT162b2 (left column) or mRNA-1273 (right column) vaccinees 604 collected at baseline (n=10 for BNT162b2 and n=10 for mRNA-1273 groups), 18.9 days (arithmetic 605 mean ±2.4 SD) after the prime (n=10 for BNT162b2 and n=10 for mRNA-1273 groups) and 19.3 606 days (arithmetic mean ±3.9 SD) after the boost (n=10 for BNT162b2 and n=10 for mRNA-1273 607 groups), were tested for IgG antibodies against irrelevant LNPs (A and B), PEGylated BSA 20kDa 608 (C and D), 3.35kDa PEG (E and F) by ELISA. Dotted line represents the limit of detection (LOD) of 609 the assay. Statistically significant differences between post-prime/post-boost vs baseline 610 antibody levels are shown. One-way ANOVA with Tukey's multiple comparisons test. *, P < 0.05; 611 **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

612

613 Figure 3. Correlation of polyethylene glycol (PEG) reactive antibodies among different assays.

Area under the curve (AUC) values obtained from the 20kDa PEGylated-BSA ELISA using mRNA-1273 sera were analyzed for correlation with BNT162b2 formulation specific IgG (**A**), mRNA-1273 formulation specific IgG (**B**), irrelevant LNPs IgG (**C**), and PEG 3.35KDa specific IgG (**D**). Pearson correlation was used. Statistically significant differences between post-prime/post-boost vs baseline antibody levels are shown. One-way ANOVA with Tukey's multiple comparisons test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

620

621 Figure 4. Levels of IgM and IgE antibodies against PEG and specificity of anti-PEG ELISA. Sera 622 from BNT162b2 (left column) or mRNA-1273 (right column) vaccinees collected at baseline (n=10 623 for BNT162b2 and n=10 for mRNA-1273 groups), 18.9 days (arithmetic mean ±2.4 SD) after the 624 prime (n=10 for BNT162b2 and n=10 for mRNA-1273 groups) and 19.3 days (arithmetic mean 625 ±3.9 SD) after the boost (n=10 for BNT162b2 and n=10 for mRNA-1273 groups), were tested for 626 IgM (A and B) or IgE (C and D) antibodies against PEGylated BSA 20kDa or against bovine serum albumin (BSA, E and F). Statistically significant differences between post-prime/post-boost vs 627 628 baseline antibody levels are shown. One-way ANOVA with Tukey's multiple comparisons test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. 629

630

631 Figure 5. Polyethylene glycol (PEG) antibodies in participants selected based on their vaccine 632 associated side effects including delayed onset injection site reactions and severe allergic

633 reaction. Sera from BNT162b2 (A) or mRNA-1273 (B) vaccinees was collected at baseline (n=28 634 for A and C, and n=19 for B and D), 14.5 days (arithmetic mean ±4.8 SD) after the prime (n=23 635 for A and C, and n=17 for B and D) or 25.2 days (arithmetic mean ±11.6 SD) after the boost (n=26 636 for A and C and n=17 for B and D), and tested for IgG (A and B), IgM (C and D) or IgE (E and F) 637 antibodies against 20kDa PEGylated BSA by ELISA. Dotted line represents the limit of detection 638 (LoD) of the assay. Statistically significant differences between post-prime/post-boost vs baseline antibody levels are shown. One-way ANOVA with Tukey's multiple comparisons test. *, P < 0.05; 639 **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. 640

641

642 **Supplementary Figure 1. Correlation of polyethylene glycol (PEG) reactive antibodies among** 643 **different assays (by vaccination time point).** Area under the curve (AUC) values obtained from 644 the 20kDa PEGylated-BSA ELISA using mRNA-1273 sera were analyzed for correlation with 645 BNT162b2 formulation specific IgG, mRNA-1273 formulation specific IgG, irrelevant LNPs IgG, and 646 3.35KDa PEG specific IgG, at baseline (left column), after the first vaccine dose administration 647 (asstral column) or often the baset (right column).

- 647 (central column) or after the boost (right column). Pearson correlation was used.
- 648
- 649 Supplementary Figure 2. Controls used for measurement of IgE antibodies and for BSA ELISAs.
- 650 The positive control used for measurement of antigen-specific IgE is shown in **A**. The positive
- 651 control used for measurement of BSA specific IgG is shown in **B**.









